You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

367 Results
Drug
Other Name(s): Lorbrena®
Feb 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    lorlatinib - For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer.
Feb 2025
Document
Document
Document
Document
Document
Document
Print This information is meant to help healthcare providers prepare for conversations with their patients ages 40 to 49 about whether breast...

Pages